Aurinia Pharmaceuticals AUPH Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $283.06M+20.4% | $235.13M+34.0% | $175.51M+31.0% | $134.03M+194% | ||
| $32.67M+15.6% | $28.25M+99.7% | $14.15M+150% | $5.66M+419% | ||
| $250.39M+21.0% | $206.89M+28.2% | $161.37M+25.7% | $128.37M+188% | ||
| 88.5%+0.5pp | 88%-4.0pp | 91.9%-3.8pp | 95.8%-1.8pp | ||
| $32.51M+56.4% | $20.79M-58.1% | $49.64M+10.3% | $44.99M-12.0% | ||
| $101.79M-40.8% | $172.03M-11.8% | $195.04M-0.7% | $196.37M+13.2% | ||
| $178.14M-25.7% | $239.82M-10.2% | $267.2M+8.8% | $245.5M+8.5% | ||
| $104.91M+2,338% | -$4.69M+94.9% | -$91.69M+17.7% | -$111.47M+38.3% | ||
| 37.1%+39.1pp | -2%+50.2pp | -52.2%+30.9pp | -83.2%+313pp | ||
| $4.33M-10.4% | $4.84M+74.2% | $2.78M+959% | $262K— | ||
| $114.16M+1,433% | $7.45M+110% | -$77.47M+27.2% | -$106.35M+41.0% | ||
| -$173.05M— | —— | $551K-69.9% | $1.83M+141% | ||
| $287.2M+4,893% | $5.75M+107% | -$78.02M+27.9% | -$108.18M+40.2% | ||
| 101.5%+99.0pp | 2.4%+46.9pp | -44.5%+36.3pp | -80.7%+316pp | ||
| $2.08+4,060% | $0.05+109% | -$0.54+28.9% | -$0.76+46.1% | ||
| $124.36M+743% | $14.76M+118% | -$80.04M+26.4% | -$108.76M+38.9% | ||
| 43.9%+37.7pp | 6.3%+51.9pp | -45.6%+35.5pp | -81.1%+309pp | ||
| $104.91M+2,338% | -$4.69M+94.9% | -$91.69M+17.7% | -$111.47M+38.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aurinia Pharmaceuticals's profit margins?
- Gross margin is 89.7% and operating margin is 41.7%, with a 100.0% net margin.
- Where does Aurinia Pharmaceuticals's income statement data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.